"The
Report PharmaPoint: Macular Edema and Macular Degeneration - Japan
Drug Forecast and Market Analysis to 2023 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
Macular
Edema is a condition where fluid accumulates on the macula, leading
to vision impairment or in severe cases even vision loss. The three
main types of ME are diabetic macular edema (DME), and macular edema
following either a central or branch retinal vein occlusion (ME-CRVO
and ME-BRVO). Age-related macular degeneration (AMD) is a painless
eye condition which leads to gradual, irreversible, loss of central
vision, and is one of the leading causes of blindness among people
aged 50 and over in the developed world. Currently the ME and AMD
markets are dominated by the use of anti-VEGF monotherapy, however,
in recent years, corticosteroid implants have been reaching the ME
market which could challenge the stronghold these drugs have in this
sector. The AMD market will see the arrival of the first therapies to
treat dry AMD, fulfilling a huge unmet need in the management of this
retinal disease, and these first-in-class therapies will strongly
drive the market growth over the next ten years. The launch of wet
AMD adjunctive therapies will also see a significant change in the
treatment of AMD patients and have a positive impact on the market
growth.
Japan
has an increasingly aging society, which will act as a significant
driver of growth in this market, along with the introduction of novel
therapies for both wet and dry AMD. The wAMD drugs, Fovista and
abicipar pegol, are expected to enter the Japanese AMD market in 2019
and 2023, respectively, while the dAMD drugs, lampalizumab and
emixustat, are both expected to enter in 2018.
View
Report At :http://www.marketresearchreports.biz/analysis/247053
Scope
- Overview of Macular Edema and
Macular Degeneration including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2013-2023.
- Analysis of the impact of key
events as well the drivers and restraints affecting Japan Macular
Edema and Macular Degeneration market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Macular Edema
and Macular Degeneration
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in Japan.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/247053
Table of Contents
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
2.1 Related Reports 14
3 Disease Overview 16
3.1 Macular Degeneration
Overview 16
3.1.1 Etiology and
Pathophysiology 18
3.1.2 Classification 22
3.1.3 Symptoms and Diagnosis 24
3.2 Macular Edema Overview 27
3.2.1 Etiology and
Pathophysiology 28
3.2.2 Classification 31
3.2.3 Symptoms and Diagnosis 32
4 Disease Management 35
4.1 Diagnosis and Treatment
Overview 35
4.1.1 Macular Edema Diagnosis
35
4.1.2 Macular Degeneration
Diagnosis 35
4.1.3 Treatment Guidelines and
Leading Prescribed Drugs 36
4.1.4 Clinical Practice 37
4.2 Japan 50
5 Competitive Assessment 54
5.1 Overview 54
5.2 Product Profiles - Major
Brands 55
5.2.1 Lucentis (ranibizumab) 55
5.2.2 Eylea (aflibercept) 65
5.2.3 Avastin (bevacizumab) 75
5.2.4 Macugen (pegaptanib
sodium) 81
5.2.5 Visudyne (verteporfin) 84
6 Unmet Need and Opportunity 89
6.1 Overview 89
6.2 Treatment for Dry AMD 90
6.2.1 Unmet Need 90
6.2.2 Gap Analysis 92
6.2.3 Opportunity 94
6.3 Longer-Acting Anti-VEGF
Drug Therapy 96
6.3.1 Unmet Need 96
6.3.2 Gap Analysis 98
6.3.3 Opportunity 98
6.4 Increased Efficacy of
Anti-VEGF Therapy for wAMD 99
6.4.1 Unmet Need 99
6.4.2 Gap Analysis 100
6.4.3 Opportunity 101
6.5 Less Invasive Drug
Formulations 101
6.5.1 Unmet Need 101
6.5.2 Gap Analysis 102
6.5.3 Opportunity 103
6.6 Awareness and Earlier
Patient Diagnosis 104
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment